Proesta

Quick links to important sections

Proesta

Method of action: Antitumour

Treatment option: Carcinoma

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Proesta

Property Description
Active ingredient Estramustine (as Estramustine phosphate sodium)
Form Oral Capsule
Pharmacological class Antineoplastic agent, Hormones/antineoplastics
General Purpose Management of disease progression
Origin Synthetic analogue

What is Proesta and What Class of Medicine is it?

Proesta is a brand-name, prescription pharmaceutical substance that contains the active ingredient Estramustine. The substance is clinically recognized for its role as an antineoplastic agent and belongs to the distinct subgroup of hormones/antineoplastics. Estramustine is a complex, synthetic analogue developed as a specialized single molecule that chemically combines two distinct active components: a potent cytotoxic moiety and an estrogenic component. This combination is a differentiating factor from standard single-agent therapies; Estramustine is structurally engineered to function with a dual-mechanism of action.


Composition, Formulation, and General Purpose

The active ingredient in Proesta is Estramustine, typically administered as its prodrug form, Estramustine phosphate sodium. Proesta is formulated as an oral capsule, making its defined route of administration oral, a convenient feature for systemic use. This medication's specialized molecular design is directly linked to its general purpose: it aims to contribute to the management of disease progression in target patient groups. Estramustine is a nitrogen mustard carbamate of estradiol. This chemical structure combines both hormonal and cytotoxic actions.


Unique Action: Combining Cytostatic and Hormonal Effects

Estramustine is distinguished by its dual-mechanism structure, which combines hormonal targeting with cellular disruption. The estrogenic component acts as a carrier to guide the molecule towards cells that express hormone receptors. Once inside, the other half of the molecule, the potent nitrogen mustard component, is released to exert a cytostatic influence, interfering with the cell’s internal structures. This concurrent action provides a highly specific strategy for limiting the progression of the targeted condition.

Regulatory References

  1. U.S. National Library of Medicine (MedlinePlus)

What side effects are possible with Proesta?

Possible Side Effects and Safety Information

The safety profile of Proesta (estramustine phosphate sodium) is officially classified by regulatory authorities based on clinical trial frequency and effects across major organ systems. The most commonly documented adverse reactions are related to the drug's hormonal component and its influence on fluid balance.


Regulatory Classification of Adverse Reactions

Adverse reactions are formally grouped by the system-organ class affected, with cardiovascular and gastrointestinal events being key areas of focus.

Frequency Classification Key Adverse Reactions (Regulatory Data)
Very Common (ge 10%) Breast tenderness, gynecomastia, fluid retention, edema, dyspnea, nausea, and diarrhea.
Common (1% to <10%) Myocardial infarction, thrombophlebitis, pulmonary emboli, congestive heart failure, lethargy, anorexia, vomiting, leukopenia, and abnormal hepatic enzymes.

Serious Adverse Reactions and Safety Constraints

The official labeling documents an increased risk for serious thromboembolic events, including myocardial infarction (heart attack), pulmonary emboli, and cerebrovascular accident (stroke). The medication is generally contraindicated in patients with active thrombophlebitis or thromboembolic disorders.

Specific population-based safety constraints apply to patients with pre-existing conditions, including those with impaired liver function (due to potential for poor metabolism) and diabetes mellitus (due to a potential decrease in glucose tolerance). Additionally, the label notes that the absorption of the medicine may be impaired by the consumption of milk, milk products, or calcium-rich foods/drugs.

Overdose and Emergency Response

The official regulatory profile for Estramustine phosphate sodium (Proesta) is constrained by the fact that no specific clinical experience with human overdosage has been officially documented. Based on this constraint, regulatory authorities reasonably expect that an overdosage episode may produce pronounced manifestations of the known adverse reactions, with gastrointestinal (GI) symptoms anticipated as the most likely prominent clinical findings.

When to Seek Urgent Medical Help

In any case of suspected overdosage, immediate medical attention must be sought to allow for clinical evaluation. Urgent contact with emergency services is required if the individual exhibits life-threatening symptoms, such as collapse, seizure activity, difficulty breathing, or unresponsiveness.

Management and Follow-up

Official documents describe specific procedural management steps, including the evacuation of gastric contents, often via gastric lavage. Treatment involves the initiation of symptomatic and supportive therapy. Furthermore, due to the drug’s profile, strict and prolonged post-overdose monitoring is mandated: hematologic and hepatic parameters must be continuously observed for a minimum duration of six weeks following the exposure. No specific antidote is mentioned or known for Proesta overdose.

Therapeutic Uses of Proesta

What Proesta Treats: Main Uses and Benefits

Proesta plays a role in the palliative management of patients who experience metastatic and/or progressive carcinoma of the prostate. The use of Proesta is relevant in contexts involving heightened systemic burden. This medication is commonly used to help with advanced prostatic carcinoma, specifically in adult male patients where the cancer is metastatic or continues to progress despite prior efforts to control it. The medication is commonly used across conditions presenting with acute episodes, including contexts such as castration-resistant prostate cancer (CRPC) and second-line therapeutic strategies.

Therapeutic Benefit and Symptom Support

Proesta is generally applied in the scenario of CRPC, meaning the condition continues to progress despite prior hormonal efforts. This medication contributes to palliative treatment by supporting the management of symptoms associated with advanced disease. This approach helps to ease pain that results from tumor burden and metastatic spread, and assists with managing local symptoms like difficulty urinating (dysuria) when symptoms relate directly to the tumor mass. It supports the patient during difficult episodes by easing distress, and is commonly used when supportive symptom management is appropriate.

Quick Fact: Relief for Disease Progression Symptoms This medication helps address symptom clusters that may become intense or disruptive, contributing to easing the overall symptom load.

Eligibility and Restrictions for Use

Who can and cannot use Proesta?

Proesta (Estramustine) is strictly approved for use only in Adult Male Patients for the palliative treatment of metastatic and/or progressive carcinoma of the prostate. Eligibility is defined by specific inclusion criteria and several absolute contraindications, as stated in official regulatory documents.

Eligibility Status Patient Populations Regulatory Basis
Contraindicated Known hypersensitivity to Estramustine, Estradiol, or nitrogen mustard components Absolute Restriction
Patients with active thrombophlebitis or active thromboembolic disorders Absolute Restriction
Restricted/Caution History of thromboembolic disorders or coronary artery disease Conditional Use
Patients with impaired liver function or renal dysfunction Conditional Use
Conditions potentially aggravated by fluid retention (e.g., congestive heart failure, epilepsy, migraine) Conditional Use
Age-Related Pediatric patients (under 18 years) Safety and efficacy not established

Use in women is not indicated. For male patients with a partner of reproductive potential, the medicine is classified as Pregnancy Category X and requires the use of contraceptive measures.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Proesta’s official interaction profile outlines specific restrictions and cautions concerning co-administration with other medicinal products and substances. The regulatory information establishes a formal prohibition against taking this medication with Live Virus Vaccines. This combination is officially restricted because Estramustine may diminish the body’s resistance, increasing the potential risk of infection from the vaccine itself.

Exposure-Altering and Timing Restrictions

A clinically significant pharmacokinetic interaction exists with substances containing calcium. This class includes foods such as milk and dairy products, as well as calcium supplements and calcium-containing antacids. Official documentation states that these products impair the oral absorption of Estramustine, leading to reduced systemic exposure.

To prevent this effect, a strict timing rule is required. Estramustine must be administered:

  • At least 1 hour before a meal or any calcium-containing product.
  • At least 2 hours after consuming a meal or any calcium-containing product.

Pharmacodynamic and Population Cautions

A pharmacodynamic consideration exists with medicines used to manage blood sugar. Estramustine may affect glucose tolerance, necessitating careful observation when co-administered with antidiabetic medicines. Finally, due to the potential for altered clearance, a specific caution is noted for patients with impaired liver function, as Estramustine may be poorly metabolized in this population.

Mechanism of Action

Proesta functions as a selective, non-steroidal antagonist of the Androgen Receptor (AR). The agent achieves selective accumulation in target tissues expressing the AR. Upon binding to the cytosolic AR, Proesta inhibits the ligand-dependent activation of the receptor. This molecular interaction prevents the conformational changes required for receptor dimerization and subsequent nuclear translocation. The drug-receptor complex is sterically hindered from entering the nucleus and binding to androgen response elements (AREs) on the DNA. Consequently, Proesta modulates the transcription of androgen-dependent genes by blocking the initiation of the signaling cascade. The downstream intracellular consequence is a functional downregulation of the AR protein, primarily achieved by accelerating its degradation within the cell. The systemic physiological modulation is the attenuation of cellular processes governed by the AR signaling axis.

Dosage and Administration Information

How Proesta is Used: Official Administration Guidelines

Proesta, containing Estramustine phosphate sodium, is administered strictly via the oral route as a capsule. The use of this medicine is defined by precise instructions regarding dose, frequency, timing, and conditions of administration, all based on official prescribing documents.


Official Dosing and Scheduling

The established regimen requires calculating a total daily dose of 14 mg per kilogram of body weight. This total amount is intended to be divided and administered in 3 or 4 doses per day.


Contextual Use Instructions

Proper administration is conditioned on the timing relative to food intake. The capsules must be swallowed whole with water on an empty stomach, requiring administration at least 1 hour before or 2 hours after meals. A critical procedural instruction is to avoid the simultaneous ingestion of milk, milk products, or any calcium-containing foods or drugs (e.g., antacids), as calcium can impair the drug's absorption.


Duration and Special Populations

Therapy should be maintained for a minimum period of 30 to 90 days before the duration of continuation is fully assessed based on the patient's response. The treatment may be continued as long as a favorable response lasts. The official label specifies that the medicine must be used with caution in patients who present with impaired hepatic function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Proesta


Evidence for Use in Advanced Progressive Carcinoma of the Prostate

Proesta was studied for its use in advanced or metastatic progressive carcinoma of the prostate. This condition involves cancer that has spread beyond the primary site and continues to advance, often referred to in studies as Castration-Resistant Prostate Cancer (CRPC) because it is progressing despite previous hormone therapy. The evidence base includes Randomized Controlled Trials (RCTs) and systematic reviews/meta-analyses that pool data from multiple trials. Research examined regimens that included Proesta, often as a component of a combination regimen, comparing these combinations against chemotherapy given alone or against other reference treatments.

These studies enrolled adult male patients who had documented progression of their cancer following initial hormonal treatments. Researchers examined how patients who were experiencing active disease progression were observed during the study period. The overall study focus was on exploring how the disease's course was monitored in settings relevant to palliative care.


Study Outcomes Measured: Survival and Biomarker Response

Clinical trials and subsequent meta-analyses monitored several key outcomes. A primary focus of the research was on Overall Survival (OS), a major measurement in clinical studies. Simultaneously, studies widely used Prostate-Specific Antigen (PSA) response rate as an important measurable outcome, evaluating whether a significant decrease in PSA levels—a biological marker—was observed.

Research examined the measurement of PSA response rate, and some pooled data reported findings related to a higher measured rate in regimens that included Proesta. These findings describe patterns observed in the studies. The research also explored other factors, such as objective tumor response (changes in measurable tumor size) and patient-reported outcomes describing perceived discomfort. Studies monitored how these outcomes related to functional capacity and how patients generally reported their quality of life.


Research Gaps and Areas of Uncertainty

While research highlights what is known, there are areas where findings were mixed. A primary uncertainty relates to the major outcome of Overall Survival. Multiple systematic reviews have reported that Overall Survival measurements for Proesta combined with chemotherapy were not found to be statistically distinct from those measured for chemotherapy alone in the studies examined.

Research describing potential patterns reported a documented increase in serious non-cancer-related adverse events, particularly those affecting the cardiovascular system. These limitations indicate that evidence quality varies across studies, and comparative evidence is lacking regarding long-term, definitive outcomes.

Frequently Asked Questions (FAQ)

Common questions about Proesta (FAQ)

Q: How does Proesta differ from other similar medicines on the market?

According to official prescribing information, Proesta is chemically unique. It is a single molecule that combines two distinct components: a cytotoxic moiety (cell-disrupting part) and an estrogenic component (hormonal part). This dual structure is a differentiating factor from standard single-agent hormone or chemotherapy drugs.

Q: Is it normal to feel a certain side effect, like fatigue or nausea, when first starting Proesta?

Official documents list nausea as a Very Common adverse reaction, meaning it occurs in 10% or more of patients. Weakness and tiredness are also reported as potential effects. These gastrointestinal and systemic side effects often occur when beginning treatment, though regulatory sources do not specify exactly how long these feelings may last.

Q: Does Proesta cause weight gain or weight loss?

According to the official product information, Proesta can cause fluid retention and edema (fluid buildup). This condition may be related to weight changes. Conversely, some patients have also reported anorexia (loss of appetite) during the clinical trials.

Q: Can Proesta affect blood pressure or heart rate?

Official warnings indicate that Proesta may cause elevated blood pressure, which is medically known as hypertension. It is also associated with cardiovascular events, including the potential to cause or worsen congestive heart failure. Regulatory documents state that blood pressure and cardiovascular status are typically monitored periodically during therapy.

Q: What are the signs of an allergic reaction to Proesta?

The official labeling notes that allergic reactions, including severe types like angioedema, have been reported in patients. Angioedema is defined as rapid swelling, often around the face, tongue, or throat. The medication is contraindicated (restricted) in individuals with a known hypersensitivity to the drug or its components.

Q: Are there any specific vitamins, minerals, or supplements that should not be taken with Proesta?

Regulatory warnings specifically advise against the simultaneous use of calcium-containing foods or drugs. This includes calcium supplements, calcium-containing antacids, and dairy products. Taking calcium simultaneously with the medication may impair absorption, potentially leading to reduced systemic exposure.

Q: Does Proesta interact with popular foods or beverages, like grapefruit juice?

Official documentation focuses on the need to avoid milk, milk products, and other calcium-rich foods because they are known to impair drug absorption. Regulatory documents do not include a specific warning or interaction listing for grapefruit juice.

Q: If I am taking a blood thinner, is Proesta safe to use?

Regulatory documents establish that Proesta increases the risk of developing thrombotic and thromboembolic disorders (blood clots). Regulatory documents list the medication as contraindicated (restricted) for patients who have active thrombophlebitis or existing thromboembolic disorders.

Q: Were the clinical trials for Proesta successful in showing a benefit?

Clinical studies examined several outcomes for Proesta, including the measurement of Prostate-Specific Antigen (PSA) response rates. Clinical research indicated that regimens including Proesta resulted in a measured PSA response rate in some patients. However, official summaries of research note that the measurement for Overall Survival was not found to be statistically distinct from chemotherapy alone in the studies examined.

Q: Is there strong research evidence supporting the long-term use of Proesta?

The duration of therapy with Proesta is determined by patient response, and some individuals in studies received treatment for over three years. However, official summaries of the research indicate that evidence quality varies across studies, and comparative evidence is lacking regarding long-term, definitive outcomes.

Q: Is it necessary to have routine blood tests or monitoring while taking Proesta?

Yes, the official labeling includes requirements for monitoring. Hepatic enzymes and bilirubin levels should be tested at appropriate intervals. Blood pressure monitoring is also recommended periodically throughout the course of treatment, and patients with conditions like diabetes require careful observation according to the label.

Q: Does Proesta affect fertility or planning for a family?

Official information notes that the medication may depress testosterone levels. Due to the potential for mutagenic effects (changes to genetic material), regulatory documents state that patients of reproductive potential should use effective contraceptive measures while receiving the medicine.

Q: Does Proesta impact mood, anxiety, or mental focus?

According to official product labeling, side effects that may affect mental state include lethargy, which is a state of tiredness or sluggishness. Other reported central nervous system effects include insomnia (difficulty sleeping), emotional lability (mood changes), anxiety, and depression.

Q: What is the expected duration of effect for a single dose of Proesta?

The medication is absorbed and then broken down into active components called metabolites. The main drug is rapidly eliminated from the blood. However, official pharmacokinetic data show that the primary active metabolites, estromustine and estramustine, have a much longer half-life, with one reaching up to 22.7 hours.

Q: If I don't notice a change right away, does that mean Proesta is not working for me?

Official prescribing documents state that the therapy should be maintained for a minimum period of 30 to 90 days. The continuation of treatment is assessed based on the patient's response and progress after this initial period, as monitored by a healthcare professional.

Q: Does Proesta have the potential for dependence or addiction?

Proesta, which contains the active ingredient Estramustine, is not categorized as a controlled substance by regulatory authorities. The official product information also reports that the medication has no known effects of drug abuse or dependence.

Q: Why is Proesta only available with a prescription from a healthcare provider?

Proesta is designated as a prescription-only medication because it is classified as an antineoplastic agent (used to treat cancer). Because it is classified as an antineoplastic agent (used to treat cancer) and is a specialized therapy, regulatory classification requires professional oversight and evaluation by a healthcare provider.

Q: Is there a generic version of Proesta available, and is it the same as the brand name?

The original brand-name product containing Estramustine phosphate sodium has been discontinued by the initial manufacturer. However, information for the original product is maintained by regulatory bodies as the Reference Listed Drug (RLD) for comparison with any approved generic versions.

Q: What is the difference between the brand name and generic version of Proesta?

The brand name and generic versions contain the same active ingredient, Estramustine phosphate sodium. Generic products are approved after demonstrating bioequivalence, meaning they are expected to perform similarly to the original Reference Listed Drug in the body. The original brand name formulation is no longer commercially available from the initial manufacturer.

Q: Is there a known cumulative effect if Proesta is taken for many years?

Pharmacokinetic studies, which track how the drug moves through the body, suggest that the parent drug itself does not appear to accumulate with long-term administration. However, the body converts the drug into active components, called metabolites, which are known to have a longer plasma half-life.

How should Proesta be stored and disposed of?

Storage and Disposal of Proesta (Estramustine)

Official labeling for Proesta (Estramustine phosphate sodium capsules) mandates specific conditions to maintain product stability and safety. The medicine must be stored in the refrigerator at a temperature between 2 C and 8 C (36 F to 46 F); freezing is prohibited.

Storage Requirements

  • Container Integrity: Keep the capsules in the original container and ensure it is tightly closed.
  • Child Safety: The product must be stored out of the sight and reach of children.

Disposal Instructions

As an antineoplastic agent, Proesta is classified as hazardous medicinal waste. Unused or expired medication must not be disposed of in household trash or flushed down the toilet. Disposal should occur through an approved drug take-back program or managed according to the instructions of a healthcare professional to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Proesta found in:

A-Z Index: